Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
47
Active, not recruiting, industry sponsors, Ophthalmology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed555
47 trials
Showing 1 to 25, recently updated first.
- Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis PigmentosaActive, not recruiting
AAVantgarde Bio SrlIndustry
NCT06591793 · 15 participants (planned) · Start Jul 2, 2024 · Primary completion Jan 2031
Drug: AAVB-081 · For: Usher Syndrome, Type 1B
Sites: Naples, Italy; London, United Kingdom · 3 sites in all
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Pivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04514653 · 146 participants · Start Aug 25, 2020 · Primary completion Oct 13, 2026
Drug: Ranibizumab; Local Steroid and 1 more · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 18 sites in all
- Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)Active, not recruiting
Ascidian Therapeutics, IncIndustry
NCT06467344 · 15 participants (planned) · Start Jun 11, 2024 · Primary completion Aug 1, 2030
Drug: ACDN-01 · For: Stargardt Disease; Cone Rod Dystrophy; Juvenile Macular Degeneration and 1 more
Sites: San Francisco, California; Gainesville, Florida; Miami, Florida · 11 sites in all
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sActive, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06928142 · 83 participants · Start Apr 23, 2025 · Primary completion Mar 13, 2027
Drug: Sibeprenlimab · For: Sjogren Disease
Sites: Riverside, California; Tujunga, California; Brandon, Florida · 63 sites in all
- Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)Active, not recruiting
Luxa Biotechnology, LLCIndustry
NCT04627428 · 18 participants · Start Apr 5, 2022 · Primary completion Aug 5, 2028
Drug: RPESC-RPE-4W · For: Dry Age-related Macular Degeneration
Sites: Beverly Hills, California; Palo Alto, California; Ann Arbor, Michigan
- A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06571045 · 984 participants · Start Aug 7, 2024 · Primary completion Jul 14, 2026
Drug: Ranibizumab; Remigromig · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 183 sites in all
- Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior UveitisActive, not recruiting
Novaliq GmbHIndustry
NCT07285070 · 20 participants (planned) · Start Mar 16, 2026 · Primary completion Dec 2026
Drug: Tacrolimus ophthalmic solution · For: Non-infectious Anterior Uveitis
Sites: Phoenix, Arizona; Miami, Florida; Waltham, Massachusetts · 6 sites in all
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05296447 · 103 participants · Start Apr 4, 2022 · Primary completion Jun 2031
Drug: Standard of Care; Aflibercept · For: Diabetic Retinopathy, DR
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 20 sites in all
- Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationActive, not recruiting
Perceive Biotherapeutics, Inc.Industry
NCT06087458 · 60 participants (planned) · Start Jun 21, 2023 · Primary completion Oct 2027
Drug: VOY-101 · For: Age-Related Macular Degeneration; Geographic Atrophy; Non-neovascular AMD and 1 more
Sites: Scottsdale, Arizona; Poway, California; Sacramento, California · 16 sites in all
- A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPivotal-lookingActive, not recruiting
EyeBiotech Ltd.Industry
NCT06957080 · 1,054 participants · Start Apr 16, 2025 · Primary completion Jan 11, 2027
Drug: Remigromig; Ranibizumab · For: Diabetic Macular Edema (DME)
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 164 sites in all
- A Clinical Study Evaluating Licaminlimab for Dry Eye DiseasePivotal-lookingActive, not recruiting
OculisIndustry
NCT07548632 · 160 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2026
Drug: licaminlimab · For: Dry Eye Disease (DED)
Sites: Aliso Viejo, California; Garden Grove, California; Glendale, California · 14 sites in all
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular DegenerationActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02286089 · 24 participants · Start Apr 1, 2015 · Primary completion Dec 31, 2021
Drug: OpRegen · For: Age-Related Macular Degeneration
Sites: San Francisco, California; Cincinnati, Ohio; Philadelphia, Pennsylvania · 7 sites in all
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaPivotal-lookingActive, not recruiting
Kyowa Kirin Co., Ltd.Industry
NCT06116916 · 185 participants · Start Jan 9, 2024 · Primary completion Oct 31, 2026
Drug: KHK4951; Aflibercept Injection · For: Diabetic Macular Edema (DME)
Sites: Mesa, Arizona; Tucson, Arizona; Arcadia, California · 87 sites in all
- A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06769048 · 150 participants · Start Jan 31, 2025 · Primary completion Dec 22, 2026
Drug: Placebo-matching BI 1584862; BI 1584862 · For: Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 44 sites in all
- A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)Active, not recruiting
MeiraGTx Ocular UK LtdIndustry
NCT06646289 · 24 participants · Start Oct 10, 2024 · Primary completion Oct 24, 2030
Drug: AAV5-hRKp.RPGR · For: X-Linked Retinitis Pigmentosa
Sites: Boston, Massachusetts; Ann Arbor, Michigan; London, United Kingdom
- Phase 2 Tolerability and Effects of ALK-001 on Stargardt DiseasePivotal-lookingActive, not recruiting
Alkeus Pharmaceuticals, Inc.Industry
NCT02402660 · 160 participants (planned) · Start Aug 2015 · Primary completion Jun 30, 2028
Drug: ALK-001; Placebo · For: Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy and 1 more
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 14 sites in all
- Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)Active, not recruiting
Alkeus Pharmaceuticals, Inc.Industry
NCT04239625 · 200 participants (planned) · Start Dec 20, 2019 · Primary completion Dec 2028
Drug: ALK-001 · For: Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy and 1 more
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 8 sites in all
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaActive, not recruiting
Eclipse Life Sciences, Inc.Industry
NCT06536491 · 75 participants (planned) · Start Aug 19, 2024 · Primary completion Oct 15, 2026
Drug: EC-104 high dose; EC-104 low dose and 1 more · For: Diabetic Macular Edema
Sites: Tampa, Florida
- Evaluate the Safety and Efficacy of TJO-087Active, not recruiting
Taejoon Pharmaceutical Co., Ltd.Industry
NCT07810972 · 90 participants · Start Apr 6, 2026 · Primary completion Oct 2026
Drug: TJO-087; TJO-087 and 1 more · For: Dry Eye Syndrome (DES)
Sites: Seoul, South Korea
- Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)Pivotal-lookingActive, not recruiting
Alcon ResearchIndustry
NCT05769153 · 139 participants · Start Dec 6, 2023 · Primary completion Apr 2027
Drug: AR-14034 SR implant lower dose; AR-14034 SR implant higher dose and 3 more · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Dothan, Alabama; Gilbert, Arizona; Phoenix, Arizona · 42 sites in all
- Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular DegenerationActive, not recruiting
SanofiSanofi (SNY)
NCT01736592 · 27 participants · Start Dec 14, 2012 · Primary completion Aug 29, 2033
Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583 · For: Stargardt's Disease
Sites: Portland, Oregon; Paris, France
- 4D-150 in Patients With Diabetic Macular EdemaActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT05930561 · 72 participants (planned) · Start Aug 9, 2023 · Primary completion Feb 28, 2029
Drug: 4D-150 IVT; Aflibercept IVT · For: Diabetic Macular Edema; Diabetic Retinopathy
Sites: Hagerstown, Maryland; Eugene, Oregon; Erie, Pennsylvania · 6 sites in all
- A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseasePivotal-lookingActive, not recruiting
OcugenIndustry
NCT05956626 · 51 participants (planned) · Start Aug 25, 2023 · Primary completion Sep 28, 2026
Drug: OCU410ST · For: Stargardt Disease
Sites: Phoenix, Arizona; Sacramento, California; Gainesville, Florida · 14 sites in all
- Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisActive, not recruiting
OcugenIndustry
NCT05203939 · 22 participants · Start Jan 24, 2022 · Primary completion Mar 2027
Drug: OCU400 Low Dose; OCU400 Med Dose and 2 more · For: Retinitis Pigmentosa; Leber Congenital Amaurosis
Sites: Phoenix, Arizona; La Jolla, California; Miami, Florida · 7 sites in all
- Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)Active, not recruiting
jCyte, IncIndustry
NCT06912633 · 31 participants · Start Jun 20, 2025 · Primary completion Dec 2026
Drug: human retinal progenitor cells · For: Retinitis Pigmentosa
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 12 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.